Skip to content

The Role of Platelet-rich Plasma Local Injection as Treatment in Improvement of Pilonidal Sinus Surgery Outcomes

Assessment of the Role of Platelet-rich Plasma Local Injection as an Additional Treatment in Improvement of Pilonidal Sinus Surgery Outcomes

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07567586
Enrollment
40
Registered
2026-05-05
Start date
2023-03-30
Completion date
2025-05-30
Last updated
2026-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pilonidal Sinus Disease, Platelet-rich Plasma, Treatment

Keywords

treatment, pilonidal sinus surgery, Platelet-rich plasma, local injection

Brief summary

The aim of the present study is to find How Platelet-rich plasma treatment improves postoperative recovery in patients with pilonidal sinus disease.

Detailed description

Pilonidal sinus disease is a chronic inflammatory condition of the skin and subcutaneous tissue that typically arises from hair follicles in the natal cleft of the sacrococcygeal region. The aetiology is debated but theorised to be a result of either the obstruction and subsequent inflammation of hair follicles, or acquired from hair penetrating through the skin into subcutaneous tissue. It is a common problem affecting 26/100,000 of the general population, with an incidence of 1.1% in young adult males. It is a troublesome disease for patients, with negative impact on quality of life, mood, employment and self-image. It also results in a significant burden for the healthcare service, with high rates of recurrence and readmission following surgery. Definitive surgical management of Pilonidal sinus disease is challenging and remains a contentious issue. The aim of surgery is for the complete excision of affected tissue followed by prompt wound healing with a minimal recurrence rate. Numerous surgical procedures have been described for this purpose without a clear consensus on an optimal approach . Following excision, options for dealing with the resulting defect include healing by secondary intention, midline primary closure or lateral closure by a variety of flap techniques. The use of Platelet-rich plasma involves a complex network of molecular events which accelerate tissue regeneration due to its richness in growth factors plus a variety of biologic mediators. Platelet-rich plasma is an autologous product studied since the late 70s. It has been used in plastic and orthopedic surgery. It has a high concentration of platelets and growth factors (VEGF, PDGF, IGF-1, EGF). Platelets are activated and the suspension is applied to the desired location, stimulating vascular proliferation and promoting tissue healing. Platelet-rich plasma has more concentrated platelets than normal plasma (approximately 150-400×103 cell/dL). The presence of GFs in Platelet-rich plasma such as transforming growth factor-β, insulin-like growth factor1 co-stimulate the stem cells and fibroblasts secretions and promotes the fibrin matrix formation which effectively drive the healing process, induces regenerative response and lead to the damage structure repair in recovery of Pilonidal sinus disease disease. The aim of the present study is to find How Platelet-rich plasma treatment improves postoperative recovery in patients with pilonidal sinus disease.

Interventions

DRUGGroup A :Platelet-rich plasma treatment

patients who are undergoing excision of pilonidal sinus disease and followed by Platelet-rich plasma treatment

DRUGGroup B: Control group

Group B: patients who are undergoing excision of pilonidal sinus disease and not followed by Platelet-rich plasma treatment.

Sponsors

Fayoum University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Patients with chronic pilonidal sinus . * Patients with recurrent pilonidal sinus. * Patients with large, painful pilonidal cyst. * Patients with multiple sinus tracks.

Exclusion criteria

* High risk for general anesthesia. * Patients with high fever (39 C ).(active infection) * Patients with bleeding rash around the wound .(inflammatory skin conditions) * Patients with infected pilonidal sinus. * Patients with autoimmune skin diseases.

Design outcomes

Primary

MeasureTime frame
Incidence of healing rate of the wound (dehiscence)One month postoperative

Secondary

MeasureTime frameDescription
Incidence of complications : like drainage state , wound infection & bleedingone month postoperativeComplications : like drainage state , wound infection \& bleeding

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 6, 2026